The Cure ThatRewrites the Typo

Some of the early Silicon Valley venture-capital stories really fascinate me — and one of my favorites has nothing to do with computers.

In 1976, a young financier named Robert Swanson cold-called a scientist named Herbert Boyer and asked for ten minutes. The ten minutes turned into hours, and they ended up talking it over at a bar. By the end of the night, they had sketched out a company built on Boyer's discovery: a way to reprogram living cells so they'd produce human medicine. Backing it looked, at the time, like a bet on science fiction.

The company was Genentech. When it went public in 1980, the stock jumped from $35 to nearly $90 in minutes — one of the hottest debuts Wall Street had ever seen. Years later, the drug giant Roche bought the whole company for about $47B. The people who got in early made many times their money.

I'm a do-it-yourself investor, always on the hunt for the next ten-bagger — a stock that turns every $1 into $10. Those are rare, and when they show up, they almost always start with a story like Genentech's: real science, patient money, and a founder willing to bet on himself.

Biotech is one of the few places that kind of payoff still happens, because a single approval or one good test result can change everything overnight. Of course, there's a catch — these stocks can drop just as fast as they climb. But almost fifty years after Genentech, I think the same kind of story is starting again. And the science behind it has come a long way.

When it comes to the biotech science itself, I lean on a few research services I pay for — and the sharpest of them just put a name in front of me. The more I dug in, the more it felt like exactly the kind of bet I'd been waiting for.

Before I tell you the company's name, I want to show you the size of what it's chasing. For most of human history, the number of people on earth barely moved. Disease, famine, and war held it in check, century after century.

Then, almost overnight — better food, clean water, vaccines, antibiotics — the line shot straight up. There are now about 8.3 billion of us, the most there have ever been, living longer than any generation before.

Population grew exponentially as starvation, plagues, and infections were defeated in most parts of the world. But there's one enemy we've barely touched — because it doesn't attack us from the outside. It's already inside us.

Think of your DNA as an instruction manual that every cell in your body follows. Sometimes a single typo in that manual causes a disease — and you can't fix a typo with clean water or a vaccine. For most of human history, no one could fix it at all. That is the last great frontier in medicine.

Across 8.3 billion people, even a disease that counts as "rare" can add up to hundreds of thousands of lives. So fixing those typos would be one of the biggest breakthroughs medicine has ever seen — and for the first time, it's genuinely within reach.

Around 2012, scientists built the first tool that could actually edit DNA. It's called CRISPR — you may have heard of it — and people nicknamed it "molecular scissors," because it works by cutting the DNA strand at the broken spot. It won a Nobel Prize. But scissors are clumsy, and cutting can cause damage you didn't intend. So one scientist in Boston spent years making the tool gentler and more precise — until his newest version didn't cut at all.

It works like the find-and-replace button in a word processor: it finds the exact typo and rewrites it, cleanly. It's the most precise version of this technology anyone has built. And one company holds the rights to it.

The company is Prime Medicine (Nasdaq: PRME), based in Cambridge, Massachusetts. It owns the rights to that find-and-replace gene-editing tool — the third and most advanced generation of the technology. And the man who runs it is the same Boston scientist behind that breakthrough: Dr. David Liu, a Harvard professor widely regarded as one of the most important figures in the field. He didn't license the tool from someone else. He invented it, then built the company to bring it to patients.

And Prime isn't Liu's first company — it's the newest in a remarkable streak. Every time he's invented a better way to edit genes, he's started a company to bring it to patients. His second-generation tool, base editing — picture a pencil that rewrites a single letter, where the first tool was scissors — became Beam Therapeutics, which he co-founded in 2017.

He even helped launch one of the very first CRISPR companies before that. So Liu has built a company at every stage of this field's history. Here's the part that matters for us: that second-generation company, Beam, is worth several times what Prime is today — even though Prime runs on his newest and most capable tool. We'll come back to that gap.

It's the same pattern as that Genentech story I opened with: a brilliant scientist betting on his own discovery, backed by investors patient enough to wait. Liu is that scientist this time around — and he owns a big piece of the company himself. He's Prime's largest shareholder, and he's been buying more of his own stock, not selling.

What makes the tool special isn't only what it can do — it's what it doesn't do. Because it never slices through the DNA, it leaves far less mess behind. In a field where the great fear is that an edit will accidentally damage something else, "cleaner" isn't a nice-to-have. It may be the whole ballgame.

A year ago, this was a promise: a beautiful tool that worked in the lab. The reason I'm writing about it now is that something changed — the promise started turning into proof.

Here's the part that made me pay attention. A year ago, the tool had only ever worked in the lab — on cells in a dish, in animals. Impressive, but unproven where it counts. Over the past year, that changed.

In a rare inherited disease called CGD — where a child's immune system can't properly fight off infection — Prime used its tool on real human cells. The cells started working normally again. And, just as importantly, the company reported no detectable accidental edits: no stray cuts, no scrambled chromosomes. In plain terms, the tool did exactly what it was supposed to, and nothing it wasn't. That is the first real-world sign that the whole platform does in people what it promised on paper.

Behind that, the pipeline is moving from "someday" to "scheduled." Prime plans to file the paperwork this year to begin human trials for two liver diseases — Wilson Disease and a condition called Alpha-1 — with the first human results expected in 2027. These aren't obscure: together they affect hundreds of thousands of people across the U.S. and Europe.

And the money worry I'd have flagged a year ago has eased. The company finished its latest quarter with about $149M in the bank — enough to fund the work well into 2027 — plus a partnership with drug giant Bristol-Myers Squibb that could pay Prime more than $3.5B over time, and expanded support from a major disease foundation. So the company got stronger on every front. The stock, meanwhile, round-tripped back to its starting line. That gap is the whole reason we're here.

Three numbers do most of the work here. Start with what's behind the company today.

It owns the best tool, and costs the least. There are three companies built on the three generations of this technology. The first-generation pioneer is worth about $5.5B. The second-generation company is Beam — the one Liu co-founded — and it's worth about $3.4B. Prime, which owns the newest and most capable generation, and which Liu also runs, is worth about $625M. Same inventor behind the last two. The newer, better tool carries barely a fifth of the price tag.

The upside is just catching up — not a fantasy. This isn't a bet that Prime cures everything. The simple version: if Prime grows into even the same neighborhood as its older, less-capable cousins, the stock is worth several times today's price. That's the measured case. A buyout by a big drug-maker — common in this corner of the market — would be the bonus on top.

And it's back at the starting line. The stock was first flagged near $3.07 last summer, briefly doubled, and sits near $3.06 today. So it's a stronger company at the same price it started — which is exactly the kind of setup I look for.

Step back to that bar in 1976. Two people, one discovery, and a bet that biology could become a business. Everyone who understood it early — and was patient — did extraordinarily well. The pattern has repeated, in different forms, ever since.

I think we're standing near the front of the next version of that story. The tool has gotten as precise as a find-and-replace command. The man who built it is running the company and buying its stock. The first proof in real patients just landed. And the market, distracted and impatient, has marked the whole thing back down to where it started.

I won't pretend to know the timing. Biology is slow and regulators are slower, and there will be scary days. But the gap between what this company owns and what it costs is the widest I've seen in a while — and it's the kind of gap that, historically, doesn't stay open forever.

The science finally works in people. The price still reads like it doesn't. That gap is the opportunity.

The same research service that put Prime in front of me also follows two biotech names I have written about before. Both just got fresh updates worth passing along — so here's where they stand today, in plain English.